Suscribirse

Number of bottles of esophageal biopsies in the evaluation of eosinophilic esophagitis and clinical outcomes - 11/08/23

Doi : 10.1016/j.clinre.2023.102142 
Andree H. Koop a , John Middleton a , Paul M. Travers b , Hassan Ghoz c, Dawn Francis a , Kenneth R. DeVault a , Maoyin Pang a,
a Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32224, USA 
b Division of Community Internal Medicine, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32224 USA 
c Department of Gastroenterology, University of Missouri, 2301 Holmes St 3rd Floor, Kansas City, MO 64108 USA 

Corresponding author at: Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, Fl 32224.Mayo Clinic Florida4500 San Pablo Rd SJacksonvilleFl32224

Highlights

Eosinophilic esophagitis is diagnosed through esophageal biopsies.
The optimal number and location of bottles for esophageal biopsies is unclear.
An increased number of bottles for esophageal biopsies can raise costs.
Patient outcomes did not differ between patients with one and two bottles.
One bottle of biopsies may be non-inferior to two in eosinophilic esophagitis.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

The number of bottles of esophageal biopsies needed for the evaluation of eosinophilic esophagitis (EoE) is unclear, despite cost differences.

Aims

Assess the clinical outcomes between patients with one and two bottles of esophageal biopsies for the assessment of EoE.

Methods

Retrospective study of adults who underwent esophagogastroduodenoscopy (EGD) for esophageal symptoms between January 2015 and June 2021 and findings of ≥15 eosinophils per high power field (eos/hpf). Patients with one bottle (1 bottle-EoE) had biopsies from the entire or proximal esophagus. Patients with two bottles had biopsies separated from the distal and proximal esophagus and were separated into those with ≥ 15 eos/hpf in both bottles (2 bottle Dif-EoE), or the distal bottle alone (2 bottle Lim-EoE). The primary outcomes were endoscopic findings at follow-up EGD as assessed by the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) and the presence of ≥15 eos/hpf.

Results

Of 85 patients with esophageal eosinophilia who met inclusion criteria, 49 had 2 bottle Dif-EoE, 18 had 2 bottle Lim-EoE, and 18 had 1 bottle-EoE. At median follow-up of 3.3–5.6 months, more patients with 1 bottle EoE had dysphagia (p = 0.029), however there were no differences in the EREFS (p = 0.14) or presence of ≥15 eos/hpf (p = 0.39). More patients with 2 bottle Dif-EoE were treated with topical steroids (16.3% vs. 0% vs. 0%, p = 0.039) and diet (20.4% vs. 0% vs. 5.6%, p = 0.05).

Conclusion

Endoscopic and histologic outcomes were similar in patients who had one and two bottles for esophageal biopsies in the evaluation of EoE.

El texto completo de este artículo está disponible en PDF.

Keywords : Dysphagia, Eosinophilia, Gastroesophageal reflux disease, Esophagogastroduodenoscopy

Abbreviations : EoE, GERD, EGD, PPI, 2 bottle Dif-EoE, 2 bottle Lim-EoE, 1 bottle-EoE, EREFS


Esquema


 Sources of funding: None
 Content from this manuscript was presented at Digestive Disease Week in San Diego, CA May 2022.


© 2023  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 47 - N° 7

Artículo 102142- août 2023 Regresar al número
Artículo precedente Artículo precedente
  • Clinicopathological characteristics of autoimmune gastritis: A single-center retrospective study
  • Xu Wang, Chun-Jing Lu, Hua Li, Jin-Yan Zhang, Jian-Wei Zheng, Na Wu, Wei-Lin Yang, Juan Yu, Wei-Feng Huang
| Artículo siguiente Artículo siguiente
  • Early life exposures as risk factors for non-esophageal eosinophilic gastrointestinal diseases
  • Elizabeth T. Jensen, Xiangfeng Dai, Ellyn Kodroff, Mary Jo Strobel, Amy Zicarelli, Sarah Gray, Amanda Cordell, Chelsea Anderson, Girish Hiremath, Evan S. Dellon

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.